This trial verified the role of trastuzumab deruxtecan, the novel anti-HER2-targeted ADC, cleaved with the topoisomerase I inhibitor, compared to SoC chemotherapy treatment, in patients with HER2 positive GC/GEJC. This evidence concerns the gene ERBB2 and gastric cancer.